Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices
Key takeaways
- The company is carrying out a voluntary correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System, it said on May 26.
- This case is separate from a correction issued in March affecting certain Omnipod 5 Pods.
- Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.
Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices Ashar Jawad Mon, June 1, 2026 at 9:14 PM GMT+7 1 min read PODD ^GSPC Insulet Corporation (NASDAQ:PODD) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. The company is carrying out a voluntary correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System, it said on May 26.
The medical device maker said it had identified a manufacturing issue during monitoring that could result in patients receiving less insulin than required, which could lead to high glucose levels and serious medical conditions like diabetic ketoacidosis (DKA).
According to Insulet Corporation’s (NASDAQ:PODD) press release, the manufacturing issue may cause insulin leakage outside the pod due to a small tear in the cannula above the skin, instead of being fully delivered into the body. This case is separate from a correction issued in March affecting certain Omnipod 5 Pods.